Dokumentdetails
ID
doi:10.1038/s41419-023-05709-z...
Autor
Jingtai, Zhi Linfei, Hu Yuyang, Qian Ning, Kang Xinwei, Yun Xin, Wang Xianhui, Ruan Dongmei, Huang Weiwei, Yang Xiangrui, Meng Tianze, Zhu Wei, Wang Xiangqian, ZhengLangue
enEditor
Nature
Kategorie
Life Sciences
Jahr
2023
Auflistungsdatum
05.04.2023
Schlüsselwörter
sorafenib carcinoma pfkfb3-mediated glycolysis supply tc effect aurora-a thyroidZusammenfassung
Thyroid cancer (TC) is the most common endocrine tumor, amongst which anaplastic thyroid carcinoma (ATC) is the most deadly.
Aurora-A usually functions as oncogenes, and its inhibitor Alisertib exerts a powerful antitumor effect in various tumors.
However, the mechanism of Aurora-A in regulating TC cell energy supply remains unclear.
In the present study, we demonstrated the antitumor effect of Alisertib and an association between high Aurora-A expression and shorter survival.
Multi-omics data and in vitro validation data suggested that Aurora-A induced PFKFB3-mediated glycolysis to increase ATP supply, which significantly upregulated the phosphorylation of ERK and AKT.
Furthermore, the combination of Alisertib and Sorafenib had a synergistic effect, further confirmed in xenograft models and in vitro.
Collectively, our study provides compelling evidence of the prognostic value of Aurora-A expression and suggests that Aurora-A upregulates PFKFB3-mediated glycolysis to enhance ATP supply and promote TC progression.
Combining Alisertib with Sorafenib has huge prospects for application in treating advanced thyroid carcinoma.
Jingtai, Zhi,Linfei, Hu,Yuyang, Qian,Ning, Kang,Xinwei, Yun,Xin, Wang,Xianhui, Ruan,Dongmei, Huang,Weiwei, Yang,Xiangrui, Meng,Tianze, Zhu,Wei, Wang,Xiangqian, Zheng, 2023, Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis, Nature
Projection-Specific Heterogeneity of the Axon Initial Segment of Pyramidal Neurons in the Prelimbic Cortex
heterogeneity projection-specific
